The NMC Health share price is down 50% this week. Is the company on life-support or should you buy?

A research report casting doubt on accounting practices at NMC (LSE: NMC) has destroyed its share price, but are things as bad as they seem?

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Things have taken a turn for the worse for shareholders in NMC Health (LSE: NMC) this week. The share price has tumbled from 2,585p on Monday to about 1,250p at the time of writing. NMC was previously well-liked, but now it is firmly out of favour.

The cause was a Muddy Waters research report that said it had “serious doubts about the company’s financial statements, including its asset values, cash balance, reported profits, and reported debt levels“. 

At the same time, Muddy also announced that it was taking a short position against NMC shares. That position benefits from a decline in the NMC share price, and Muddy got what it wanted.

NMC has now responded to the claims. Has Muddy made a misdiagnosis? I don’t think so.

Bad medicine

NMC valued its assets at $3.47b at the end of June 2019. Goodwill accounts for $1.44b of those assets. This goodwill asset came from acquisitions and represents the premium NMC paid above the estimated market value of the acquired assets.

If NMC grossly overpaid for its acquisitions, which Muddy suggests it did, then 41% of the assets are liable to substantial write-downs in the future. That is worrying, even if, as the company has said in response to Muddy’s report, that it valued its acquisitions fairly and had third-party valuations done as well.

Fighting back

NMC has said that when its suppliers get paid by a financier, who is later reimbursed by NMC at the original invoice amount, that amount is recognised in trade payables as it should be. Muddy Waters claims these invoices are an off-balance sheet source of financing. Since NMC has not broken down its trade payables, I cannot say much more.

Muddy Waters believes NMC has inflated its cash and equivalents balances because they attract negligible interest. I took the average of the opening and closing balances for the first six months of this year, which, with the half-year finance income number, means NMC gets about 1.9% interest annually on its cash balances.

That’s not far away from the 2% NMC claims you get on cash deposits in the Middle East. The rate makes sense if NMC needs most of its cash to support working capital and therefore places it in short-term, deposit-like accounts, as it claims it does.

Diagnosis

If the bulk of those cash balances are needed to support working capital, then announcing a $200m share buyback seems potentially ruinous.

Sure, the NMC share price was in freefall, and its management probably thought a buyback announcement might shore it up. However, the buyback consumes nearly 50% of NMC’s cash and equivalents if carried out in full, which means it can’t be done in full without taking on additional debt.

Furthermore, on Tuesday NMC announced it wanted to buy back $90m of convertible bonds issued just last year. Is that going to eat into working capital cash, or is more debt going to be issued? At the very least, it means that NMC management appears to have issued $90m of debt needlessly.

NMC has not convinced me that the allegations made by Muddy Waters are baseless. There are inconsistencies in the company’s defence. The 39-page report issued by Muddy Waters is available for download and it raises many more issues than I have been able to cover here. I will avoid this stock.

James J. McCombie has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

I asked ChatGPT to name 3 epic growth stocks to buy in 2026 and it said…

Harvey Jones is looking to inject some excitement into his portfolio this year and wondered if ChatGPT could suggest some…

Read more »

Businessman using pen drawing line for increasing arrow from 2024 to 2025
Investing Articles

What £10,000 invested in Babcock’s and BAE Systems’ shares 1 year ago is worth today…

Harvey Jones says BAE Systems' shares have been going great guns while fellow FTSE 100 defence stock Babcock has shot…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

Lloyds’ share price near £1: has the easy money already been made?

With the Lloyds share price struggling to break above £1, Mark Hartley questions whether its years-long rally has come to…

Read more »

Emma Raducanu for Vodafone billboard animation at Piccadilly Circus, London
Investing Articles

Can the Vodafone share price reach £1.50 in 2026?

The Vodafone share price had a great year in 2025, rising by 41.4%. Muhammad Cheema takes a look at whether…

Read more »

Investing Articles

Which UK stocks can outperform in 2026?

Slow growth, lower inflation, rising unemployment – what does it all mean for investors looking for UK stocks that can…

Read more »

US Stock

Warren Buffett’s advice about the best investment you can make looks more relevant than ever in 2026

Warren Buffett doesn’t really need to use artificial intelligence. But his advice on investing is more relevant than ever in…

Read more »

Dividend Shares

2 FTSE 250 dividend shares yielding over 10% I like for 2026

Jon Smith reviews a couple of FTSE 250 companies with double-digit yields he feels have positive outlooks for the coming…

Read more »

Portrait of pensive bearded senior looking on screen of laptop sitting at table with coffee cup.
Investing Articles

This FTSE 100 stock tanked in 2025. Can it rebound in 2026?

The FTSE 100 index soared last year, but shares in the owner of the UK's stock exchange plummeted. Will they…

Read more »